KPTI, US48576U2050

Karyopharm stock: November 2 is the estimated results date for Karyopharm stock

Published on 10/22/2026 at 22:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter revenue was USD 33.43 million versus USD 37.90 million. Karyopharm stock costs EUR 0.51 on October 22, 2026 at 10:48 p.m. CEST.

Reporting date and revenue

Karyopharm Therapeutics is estimated to report third-quarter results on November 2, 2026.
Second-quarter revenue was USD 33.43 million versus USD 37.90 million a year earlier.
Karyopharm stock costs EUR 0.51 at Lang & Schwarz on October 22, 2026 at 10:48 p.m. CEST.

KPTI, US48576U2050, Illustration mit AI erstellt.

Karyopharm Therapeutics stock (ISIN US48576U2050) has an estimated November 2, 2026 date for its third-quarter results, MarketBeat reports. The company generated USD 33.43 million in second-quarter revenue, according to Yahoo Finance. The stock was trading at EUR 0.51 at Lang & Schwarz on October 22, 2026 at 10:48 p.m. CEST.

Revenue remains below last year

Karyopharm's second-quarter revenue fell to USD 33.43 million from USD 37.90 million in the second quarter of 2025. The earnings call attributed the decline partly to the end of Menarini reimbursement for development-related expenses, which reduced revenue by USD 6.50 million year over year, according to Yahoo Finance.

For the third quarter, the consensus revenue estimate is USD 31.59 million, compared with USD 33.43 million in the second quarter. Business Quant also lists a consensus earnings-per-share estimate of minus USD 0.90 for the period.

Nasdaq quote stays highly volatile

On Nasdaq, KPTI was last quoted at USD 0.55 on October 22, 2026 at 4:00 p.m. ET. Its 52-week range was USD 0.31 to USD 10.99, while market capitalization stood at USD 12.4 million. The quote's negative P/E of minus 0.04 reflects the company's reported loss position.

November 2 is the next date

The next scheduled item is the estimated third-quarter results announcement on November 2, 2026, before the market opens, with an earnings call planned for 8:00 a.m. ET, according to MarketBeat. Karyopharm's investor-relations materials identify Nasdaq ticker KPTI and describe the company as a commercial-stage biotechnology business focused on cancer therapies, including XPOVIO, its selinexor product.

Price context for investors

The German-market indication places the stock at EUR 0.51 at Lang & Schwarz on October 22, 2026 at 10:48 p.m. CEST. The primary-market quote was USD 0.55 on Nasdaq at the latest completed regular-session timestamp.

The further course of trading is shown by the continuously updated real-time quote of Karyopharm Therapeutics stock.